Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME3ZYC)

Drug Name

ALKS 4230 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin 2 receptor (IL2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Denileukin diftitox	DMMHR1U	Epithelial ovarian cancer	2B5D	Approved	[3]
Ro26-4550	DMGL7TM	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04592653) A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment (ARTISTRY-3). U.S. National Institutes of Health.
2	ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673.
3	Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2297).